{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"bioAffinity Technologies, Inc."},"Symbol":{"label":"Symbol","value":"BIAF"},"Address":{"label":"Address","value":"United States"},"Phone":{"label":"Phone","value":""},"Industry":{"label":"Industry","value":"Biotechnology: Commercial Physical & Biological Resarch"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company is involved in developing technologies that, in the future, will be able to detect and monitor diseases of the lung and other cancers and treat many cancers."},"CompanyUrl":{"label":"Company Url","value":"https://www.bioaffinitytech.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"David Elzi","title":"Vice President-Research"},{"name":"Maria Zannes","title":"President, Chief Executive Officer & Director"},{"name":"Xavier T. Reveles","title":"Chief Operating Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}